Skip to main content
SpringerLink
Log in

VEGF-Inhibition in Macular Telangiectasia Type 2

  • Chapter
  • First Online:
Anti-Angiogenic Therapy in Ophthalmology

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

  • 960 Accesses

Abstract

Macular telangiectasia (MacTel) type 2 is a bilateral disease with characteristic degenerative changes of the central retina and leakage of telangiectatic macular capillaries. Depending on the development of secondary neovascularizations, a non-proliferative and a proliferative (neovascular) disease stage is distinguished. Patients with proliferative MacTel type 2 may benefit from short-term intravitreal VEGF-inhibition. However, there is no evidence for an effective treatment of non-proliferative MacTel type 2 and possibly, some therapeutic approaches including VEGF-inhibition might even promote disease progression.

Parts of the text of this chapter have been modified from Charbel Issa P, Gillies MC. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77. doi:10.1016/j.preteyeres.2012.11.002.Epub2012Dec3.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina. 2003;23(1):113–6.

    Article  PubMed  Google Scholar 

  • Arevalo JF, Sanchez JG, et al. Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2007;245(11):1673–80.

    Article  CAS  PubMed  Google Scholar 

  • Berger AS, McCuen 2nd BW, et al. Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina. 1997;17(2):94–8.

    Article  CAS  PubMed  Google Scholar 

  • Cakir M, Kapran Z, et al. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol. 2006;16(5):711–7.

    CAS  PubMed  Google Scholar 

  • Charbel Issa P, Holz FG, et al. Findings in fluorescein angiography and optical coherence tomography after intravitreal Bevacizumab in Type 2 idiopathic macular telangiectasia. Ophthalmology. 2007a;114(9):1736–42.

    Article  PubMed  Google Scholar 

  • Charbel Issa P, Scholl HPN, et al. Short-term effects of intravitreal bevacizumab in Type II idiopathic macular telangiectasia. Retin Cases Brief Rep. 2007b;1(4):189–91. doi:10.1097/ICB.0b013e31802efef2.

    Article  PubMed  Google Scholar 

  • Charbel Issa P, Finger RP, et al. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol. 2008;92(7):941–5.

    Article  CAS  PubMed  Google Scholar 

  • Charbel Issa P, Scholl HP, et al. Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. Eye. 2009;23(2):435–41.

    Article  CAS  PubMed  Google Scholar 

  • Charbel Issa P, Troeger E, et al. Structure-function correlation of the human central retina. PLoS One. 2010;5(9):e12864.

    Article  PubMed  PubMed Central  Google Scholar 

  • Charbel Issa P, Finger RP, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol. 2011;151(5):876–86. e871.

    Article  PubMed  Google Scholar 

  • Charbel Issa P, Gillies MC, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77.

    Article  CAS  PubMed  Google Scholar 

  • Chew EY, Clemons TE, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol. 2015;159(4):659–66. e651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chopdar A. Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. Br J Ophthalmol. 1978;62(4):243–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davidorf FH, Pressman MD, et al. Juxtafoveal telangiectasis-a name change? Retina. 2004;24(3):474–8.

    Article  PubMed  Google Scholar 

  • De Lahitte GD, Cohen SY, et al. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol. 2004;138(5):892–4.

    Article  PubMed  Google Scholar 

  • Eandi CM, Ober MD, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina. 2006;26(7):780–5.

    Article  PubMed  Google Scholar 

  • Engelbrecht NE, Aaberg Jr TM, et al. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol. 2002;120(3):320–4.

    Article  PubMed  Google Scholar 

  • Finger RP, Charbel Issa P, et al. Reading performance is reduced due to parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2009;50(3):1366–70.

    Article  PubMed  Google Scholar 

  • Friedman SM, Mames RN, et al. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg. 1993;24(8):551–3.

    CAS  PubMed  Google Scholar 

  • Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100(10):1536–46.

    Article  CAS  PubMed  Google Scholar 

  • Gaudric A, Ducos de Lahitte G, et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 2006;124(10):1410–9.

    Article  PubMed  Google Scholar 

  • Gillies MC, Zhu M, et al. Familial asymptomatic macular telangiectasia type 2. Ophthalmology. 2009;116(12):2422–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Heeren TF, Holz FG, et al. First symptoms and their age of onset in macular telangiectasia Type 2. Retina. 2013;34(5):916–9.

    Article  Google Scholar 

  • Hershberger VS, Hutchins RK, et al. Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging. 2003;34(4):318–20.

    PubMed  Google Scholar 

  • Hussain N, Das T, et al. Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis. Am J Ophthalmol. 2005;140(2):333–5.

    Article  PubMed  Google Scholar 

  • Hutton WL, Snyder WB, et al. Focal parafoveal retinal telangiectasis. Arch Ophthalmol. 1978;96(8):1362–7.

    Article  CAS  PubMed  Google Scholar 

  • Jorge R, Costa RA, et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol. 2007;245(7):1045–8.

    Article  CAS  PubMed  Google Scholar 

  • Kupitz EH, Heeren TFC et al. (2015). Long-term poor outcome of anti-VEGF therapy in non-proliferative macular telangiectasia type 2. Retina [in press].

    Google Scholar 

  • Kurihara T, Westenskow PD, et al. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012;122(11):4213–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee BL. Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. Retina. 1996;16(4):344–6.

    Article  CAS  PubMed  Google Scholar 

  • Maia Jr OO, Bonanomi MT, et al. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol. 2007;144(2):296–9.

    Article  PubMed  Google Scholar 

  • Mandal S, Venkatesh P, et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2007;245(12):1825–9.

    Article  CAS  PubMed  Google Scholar 

  • Martinez JA. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol. 2003;121(11):1658–9.

    Article  PubMed  Google Scholar 

  • Matt G, Sacu S, et al. Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye (Lond). 2010;24(10):1535–41.

    Article  CAS  Google Scholar 

  • Narayanan R, Chhablani J, et al. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina. 2012;32(10):2001–5.

    Article  CAS  PubMed  Google Scholar 

  • Park D, Schatz H, et al. Fibrovascular tissue in bilateral juxtafoveal telangiectasis. Arch Ophthalmol. 1996;114(9):1092–6.

    Article  CAS  PubMed  Google Scholar 

  • Park DW, Schatz H, et al. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology. 1997;104(11):1838–46.

    Article  CAS  PubMed  Google Scholar 

  • Potter MJ, Szabo SM, et al. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol. 2002;133(1):149–51.

    Article  PubMed  Google Scholar 

  • Potter MJ, Szabo SM, et al. Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can J Ophthalmol. 2006;41(1):34–7.

    Article  PubMed  Google Scholar 

  • Powner MB, Gillies MC, et al. Perifoveal Müller cell depletion in a case of macular telangiectasia type 2. Ophthalmology. 2010;117(12):2407–16.

    Article  PubMed  PubMed Central  Google Scholar 

  • Powner MB, Gillies MC, et al. Loss of Muller’s cells and photoreceptors in macular telangiectasia type 2. Ophthalmology. 2013;120(11):2344–52.

    Article  PubMed  Google Scholar 

  • Roller AB, Folk JC, et al. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina. 2011;31(9):1848–55.

    Article  CAS  PubMed  Google Scholar 

  • Shanmugam MP, Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol. 2005;53(1):61–3.

    Article  PubMed  Google Scholar 

  • Shanmugam MP, Mythri HM, et al. Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane. Indian J Ophthalmol. 2007;55(6):490–1.

    Article  PubMed  PubMed Central  Google Scholar 

  • Shen W, Fruttiger M, et al. Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. J Neurosci. 2012;32(45):15715–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shukla D, Singh J, et al. Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am J Ophthalmol. 2004;138(1):147–9.

    Article  PubMed  Google Scholar 

  • Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol. 2004;138(5):884–5.

    Article  CAS  PubMed  Google Scholar 

  • Snyers B, Verougstraete C, et al. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol. 2004;137(5):812–9.

    Article  CAS  PubMed  Google Scholar 

  • Toy BC, Koo E, et al. Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina. 2012;32(5):996–1006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Watzke RC, Klein ML, et al. Long-term juxtafoveal retinal telangiectasia. Retina. 2005;25(6):727–35.

    Article  PubMed  Google Scholar 

  • Wurm A, Pannicke T, et al. Glial cell-derived glutamate mediates autocrine cell volume regulation in the retina: activation by VEGF. J Neurochem. 2008;104(2):386–99.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Bonn, Ernst Abbe Strasse 2, Bonn, 53127, Germany

    Peter Charbel Issa M.D., D.Phil. & Frank G. Holz M.D.

Authors
  1. Peter Charbel Issa M.D., D.Phil.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank G. Holz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Charbel Issa M.D., D.Phil. .

Editor information

Editors and Affiliations

  1. Eye Center at the Medical Center, University of Freiburg, Freiburg, Baden-Württemberg, Germany

    Andreas Stahl

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Charbel Issa, P., Holz, F.G. (2016). VEGF-Inhibition in Macular Telangiectasia Type 2. In: Stahl, A. (eds) Anti-Angiogenic Therapy in Ophthalmology. Essentials in Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-24097-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-24097-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-24095-4

  • Online ISBN: 978-3-319-24097-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation